Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor
Phase of Trial: Phase III
Latest Information Update: 19 Oct 2017
At a glance
- Drugs Retosiban (Primary) ; Atosiban
- Indications Preterm labour
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 12 Oct 2017 Planned End Date changed from 16 Aug 2017 to 31 Oct 2017.
- 09 Oct 2017 Status changed from active, no longer recruiting to discontinued.
- 30 Sep 2017 This study has been completed in Germany (On-2017-08-25 ) as per European Clinical Trials Database record.